INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The company's product platform consists of INKmune and INB03. INKmune is a natural killer cell therapeutic which primes the patient's NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio Inc. is based in La Jolla, United States.
| Revenue (Most Recent Fiscal Year) | $0.01M |
| Net Income (Most Recent Fiscal Year) | $-42.08M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.71 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -111016.00% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -120.62% |
| Return on Assets (Trailing 12 Months) | -92.94% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.20 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.20 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.09 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.34 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.11 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.48 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 26.58M |
| Free Float | 17.09M |
| Market Capitalization | $55.56M |
| Average Volume (Last 20 Days) | 2.02M |
| Beta (Past 60 Months) | 0.97 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 35.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 12.72% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |